SARS-CoV-2 conserved T-cell epitopes from non-spike viral proteins (Non-spike T-cell epitopes)

SARS-CoV-2 conserved T-cell epitopes from non-spike viral proteins are specific peptide sequences derived from stable regions of the virus, such as the Nucleocapsid (N), Membrane (M), and non-structural proteins (NSPs) like NSP12 (RNA-dependent RNA polymerase). Unlike the Spike protein, which frequently mutates to evade neutralizing antibodies, these internal proteins are highly conserved across different SARS-CoV-2 variants and even other betacoronaviruses (Nature, 2021). These epitopes serve as therapeutic targets for next-generation vaccines and immunotherapies designed to elicit robust cellular immunity. When presented by Major Histocompatibility Complex (MHC) molecules, they activate CD8+ cytotoxic T cells to kill infected cells and CD4+ helper T cells to coordinate the immune response (Cell Reports Medicine, 2022). This approach aims to provide variant-proof protection by targeting viral components that are essential for the virus's life cycle and less tolerant of mutations. Clinical candidates like GRT-R910 and UB-612 are currently exploring these targets to enhance the breadth and durability of vaccine-induced protection (Gritstone Bio, 2023; Vaxxinity, 2023).

Other names

Conserved SARS-CoV-2 T-cell antigensNon-spike structural and non-structural protein epitopesPan-variant T-cell epitopesSARS-CoV-2 internal protein epitopes

Stimulation of CD4+ and CD8+ T-cell responses via MHC-mediated antigen presentation to provide broad-spectrum protection against viral variants.